Akcea Theraps patents expiration
1. Tegsedi patents expiration
TEGSEDI Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7015315 | AKCEA THERAPS | Gapped oligonucleotides |
Mar, 2023
(1 year, 1 month ago) | |
| US7101993 | AKCEA THERAPS | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(7 months ago) | |
| US8101743 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2025
(11 months from now) | |
| US9061044 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399774 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(7 years from now) | |
| US8697860 | AKCEA THERAPS | Diagnosis and treatment of disease |
Apr, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
TEGSEDI family patents
